Upcoming CRO/CMO Symposium To Address Drug Development Journey

PCI Synthesis, a Contract Manufacturing Organization (CMO), announced in a press release that a record number of exhibitors and attendees are expected at the third annual Massachusetts CRO/CMO Symposium. The event showcases biotech companies that support the pharmaceutical industry. The conference will be held on May 5 from 7:30 a.m. to 6:00 p.m. at the Burlington Marriott in Burlington, Mass.

The CRO/CMO Symposium

The symposium is in its third year and includes exhibits by more than 45 CROs and CMOs. Over three hundred attendees are expected. Participants can network with the exhibitors, take part in interactive panel discussions, and hear case presentations. Some of the conference events include:

• Sixteen roundtable discussions including the benefits of strong relationships in transferring technology and utilizing CROs and CMOs, biomarker development and its increasing emphasis by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), and challenges in recruiting clinical trial participants for rare diseases.
• A "Fireside Chat" on the topic of "Simplifying the Drug Development Journey from Research to Treatment." The facilitator is John Reddington, COO of Cambridge Biomedical, and speakers include Mark Goldberg, President and COO of PAREXEL International Corp.

Edward S. Price, CEO, PCI Synthesis and co-chair of the MassBio CRO/CMO cluster said, "The biotech and life sciences industries have grown in importance to the Boston area over the past three years and play a national role in drug discovery and development. With GDUFA and other changing regulations, it is more important than ever we keep the dialog going around drug development."

MassBio is a not-for-profit organization representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations. It works in health care and the life sciences to provide education and industry services.